Mark Lebwohl, MD, discusses patient preferences and clinical features favoring oral therapy over biologics in patients with moderate to severe plaque psoriasis.
Behind the Data: Envudeucitinib's Safety & Efficacy in Psoriasis
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
Beyond Dry Skin: Rethinking Common Eczema Misconceptions
3
FDA Revises TB Evaluation Guidance for SKYRIZI
4
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
5